

UNITED STATES OF AMERICA
before the
SECURITIES AND EXCHANGE COMMISSION

SECURITIES EXCHANGE ACT OF 1934
Release No. 87527 / November 13, 2019

Admin. Proc. File No. 3-19273

In the Matter of

BIOLOG, INC., BOZKI, INC., and CHINA GEWANG
BIOTECHNOLOGY, INC.

ORDER TO SHOW CAUSE

The Securities and Exchange Commission (“Commission”) issued an order instituting administrative proceedings (“OIP”) on July 24, 2019, pursuant to Section 12(j) of the Securities Exchange Act of 1934, against Biolog, Inc., Bozki, Inc., and China Gewang Biotechnology, Inc.¹ On August 26, 2019, the Commission accepted an Offer of Settlement submitted by Bozki, Inc.²

On August 15, 2019, the Division of Enforcement filed the Declaration of Gina Joyce, which stated that, consistent with Rule 141(a)(2)(ii) of the Commission’s Rules of Practice,³ service of the OIP was made on Biolog, Inc., on July 27, 2019, and service of the OIP was made on the registered agent of China Gewang Biotechnology, Inc., on July 26, 2019. On November 7, 2019, the Division filed a motion requesting that the Commission find Biolog, Inc., and China Gewang Biotechnology, Inc., in default for not filing answers and that it revoke the registration of each class of their securities based on the record and the allegations in the OIP.

As stated in the OIP, the answers of Biolog, Inc., and China Gewang Biotechnology, Inc., were required to be filed within ten days of service of the OIP.⁴ As of the date of this order, Biolog, Inc., and China Gewang Biotechnology, Inc., have not filed answers. The prehearing conference and the hearing are thus continued indefinitely.

¹ *Biolog, Inc.*, Exchange Act Release No. 86453, 2019 WL 3484127 (July 24, 2019).

² *Biolog, Inc.*, Exchange Act Release No. 86768, 2019 WL 4044064 (Aug. 26, 2019).

³ 17 C.F.R. § 201.141(a)(2)(ii).

⁴ *Biolog, Inc.*, 2019 WL 3484127, at *2.

Accordingly, Biolog, Inc., and China Gewang Biotechnology, Inc., are ORDERED to SHOW CAUSE by November 27, 2019, why the registration of their securities should not be revoked by default due to their failures to file an answer and to otherwise defend this proceeding. When a party defaults, the allegations in the OIP will be deemed to be true and the Commission may determine the proceeding against that party upon consideration of the record without holding a public hearing.

If Biolog, Inc., and China Gewang Biotechnology, Inc., fail to respond to this order to show cause, they may be deemed in default, the proceeding may be determined against them, and the registration of their securities may be revoked.⁵ Upon review of the filings in response to this order, the Commission will either direct further proceedings by subsequent order or issue a final order resolving the matter.

For the Commission, by the Office of the General Counsel, pursuant to delegated authority.

Vanessa A. Countryman
Secretary

⁵ Rules of Practice 155, 180, 17 C.F.R. §§ 201.155, .180; *see Biolog, Inc.*, 2019 WL 3484127, at *2 (“If Respondents fail to file the directed Answers, . . . [they] may be deemed in default and the proceedings may be determined against them . . .”).